Agios Reports First Quarter 2026 Financial Results and Provides Business Update CAMBRIDGE, Mass., Apr. 29, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial- stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the first quarter ended March 31, 2026. "Our first-quarter performance reflects strong execution and significant progress against our 2026 strategic objectives," said Brian Goff, Chi ...